Actively Recruiting
Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer
Led by Latin American Cooperative Oncology Group · Updated on 2024-06-04
444
Participants Needed
18
Research Sites
498 weeks
Total Duration
On this page
Sponsors
L
Latin American Cooperative Oncology Group
Lead Sponsor
G
Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Phase III randomized clinical trial evaluating the sequencing of anthracyclines and taxanes in neoadjuvant therapy for locally advanced HER2-negative breast cancer.
CONDITIONS
Official Title
Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female participants aged 18 years or older
- Diagnosed with invasive breast carcinoma stage III (RH positive) or stage IIB/III (RH negative) confirmed by histology, HER2-negative
- Provide written informed consent
- Agree to use contraception during treatment and for at least 120 days after last dose
- Have functional capacity with ECOG score 0 to 2 assessed within 7 days before inclusion
- Have adequate organ function with tests done within 60 days before treatment start
- Have adequate cardiac function assessed by echocardiogram or MUGA within 60 days before treatment
You will not qualify if you...
- Individuals who do not meet the above inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO)
Cachoeiro de Itapemirim, Espírito Santo, Brazil, 29.308-065
Actively Recruiting
2
Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel
Salvador, Estado de Bahia, Brazil, 400.50-410
Actively Recruiting
3
Centro de Pesquisa do Hospital Araújo Jorge
Goiânia, Goiás, Brazil, 74.605-010
Actively Recruiting
4
ICTR - Instituto do Câncer e Transplante de Curitiba
Curitiba, Paraná, Brazil, 80.510-130
Actively Recruiting
5
HUEM/CEON - Hospital Universitário Evangélico Mackenzie
Curitiba, Paraná, Brazil, 80.730-150
Actively Recruiting
6
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil, 81.520-060
Actively Recruiting
7
IMIP - Instituto de Medicina Integral Professor Fernando Figueira
Recife, Pernambuco, Brazil, 50.070-902
Actively Recruiting
8
Hospital Universitário Oswaldo Cruz (UNIPECLIN)
Recife, Pernambuco, Brazil, 50.110-130
Actively Recruiting
9
HINJA - Hospital Jardim Amália
Volta Redonda, Rio de Janeiro, Brazil, 27.251-260
Actively Recruiting
10
HCPA - Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90.035-903
Actively Recruiting
11
CEPON - Centro de Pesquisas Oncológicas
Florianópolis, Santa Catarina, Brazil, 88.034-000
Actively Recruiting
12
Hospital de Amor de Barretos
Barretos, São Paulo, Brazil, 14.784-400
Actively Recruiting
13
UNESP - Faculdade de Medicina da Universidade Estadual Paulista (UPECLIN)
Botucatu, São Paulo, Brazil, 18.618-686
Actively Recruiting
14
Faculdade de Ciências Médicas da Unicamp
Campinas, São Paulo, Brazil, 13.083-881
Actively Recruiting
15
Hospital de Amor Jales - Hospital de Câncer de Barretos
Jales, São Paulo, Brazil, 15.706-396
Actively Recruiting
16
INCA - Instituto Nacional de Câncer
Rio de Janeiro, Brazil, 20.230-130
Actively Recruiting
17
ICESP - Instituto do Câncer do Estado de São Paulo
São Paulo, Brazil, 01.246-000
Actively Recruiting
18
IBCC Oncologia - Núcleo de Pesquisa São Camilo
São Paulo, Brazil, 04.014-002
Actively Recruiting
Research Team
D
Diana Rostirolla
CONTACT
L
Laura Voelcker
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here